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Abstract
Background: Recent studies have shown that adverse drug reactions (ADRs) are underreported.
This may be particularly true of ADRs associated with complementary and alternative medicine
(CAM). Data on CAM-related ADRs, however, are sparse.
Objective was to evaluate the impact of an educational intervention and monitoring programme
designed to improve physician reporting of ADRs in a primary care setting.
Methods: A prospective multicentre study with 38 primary care practitioners specialized in CAM
was conducted from January 2004 through June 2007. After 21 month all physicians received an
educational intervention in terms of face-to-face training to assist them in classifying and reporting
ADRs. The study centre monitored the quantity and quality of ADR reports and analysed the
results.
To measure changes in the ADR reporting rate, the median number of ADR reports and
interquartile range (IQR) were calculated before and after the educational intervention. The pre-
intervention and post-intervention quality of the reports was assessed in terms of changes in the
completeness of data provided for obligatory items. Interrater reliability between the physicians
and the study centre was calculated using Cohen's kappa with a 95% confidence interval (CI). We
used Mann Whitney U-test for testing continuous data and chi-square test was used for categorical
data. The level of statistical significance was set at P < 0.05.
Results: A total of 404 ADRs were reported during the complete study period. An initial 148%
increase (P  = 0.001) in the number of ADR reports was observed after the educational
intervention. Compared to baseline the postinterventional number of ADR reportings was
statistically significant higher (P < 0.005) through the first 16 months after the intervention but not
significant in the last 4-month period (median: 8.00 (IQR [2.75; 8.75]; P = 0.605). The completeness
of the ADR reports increased from 80.3% before to 90.7% after the intervention. The
completeness of the item for classifying ADRs as serious or non-serious increased significantly (P
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< 0.001) after the educational intervention. The quality of ADR reports increased from kappa 0.15
(95% CI: 0.08; 0.29) before to 0.43 (95% CI: 0.23; 0.63) after the intervention.
Conclusion: The results of the present study demonstrate that an educational intervention can
increase physician awareness of ADRs. Participating physicians were able to incorporate the
knowledge they had gained from face-to-face training into their daily clinical practice. However, the
effects of the intervention were temporary.
Background
The World Health Organization defines adverse drug reac-
tions (ADRs) as 'a reaction which is noxious and unin-
tended and which occurs at doses normally used in
humans for prevention, diagnosis or therapy of disease, or
for the modification of physiological functions' [1]. ADRs
are considered to be a leading cause of morbidity and
mortality [2]. Indeed, it has been shown that approxi-
mately 5.3% of hospital admissions were associated with
ADRs [3].
Although conventional clinical studies on efficacy and
safety are suitable for recognizing frequent ADRs and are
required for the approval of a new drug, they often fail to
detect rare ADRs [4]. As a result, a number of spontaneous
reporting systems have been developed in recent decades
to help detect serious, rare, and unexpected ADRs. These
systems are characterized, however, by a high rate of
underreporting, which varies depending on the types of
ADRs and drugs in question [5]. A systematic review about
determinants of under-reporting found that a large pro-
portion of physicians did not report ADRs because they
felt that these were well known or too trivial [6]. However
the knowledge and attitudes of health professionals
appear to be strongly related with reporting and are poten-
tially modifiable factors [7].
Educational interventions have been shown to influence
reporting rates [8-10]. In a cluster-randomized controlled
trial in Portugal, a 10-fold increase in the rate of ADR
reports was observed following an educational interven-
tion [8]. In contrast to the targeted outreach visits
employed in the Portuguese study, however, a solely pas-
sive method of dissemination based on mailing educa-
tional materials to selected clinicians did not lead to any
improvements in the reporting of ADRs in another study
[11].
Over the past 20 years, the use of complementary and
alternative medicine (CAM), including homeopathic,
anthroposophic, and herbal treatment, has increased
markedly in Western industrialized nations [12,13]. This
has created a challenging situation when it comes to
detecting, evaluating, and reporting ADRs, because many
patients – and, remarkably, even CAM physicians –
believe that these kinds of treatments are not associated
with risk [5]. Patient surveys have suggested that this
assumption may be traced to the belief that CAM products
are 'natural' and therefore harmless [14]. Assumptions
like these have led to a discrepancy between the growing
interest in CAM remedies and the limited data on their
potential to cause ADRs [13,15-17]. The seriousness of
this situation is compounded by the poor quality of most
individual ADR reports [18].
The aim of the present study was therefore to analyse the
impact of a face-to-face educational intervention and on
the quantity and quality of ADR reports filed by a network
of 38 CAM physicians working in the primary care sector
in Germany. To assess the sustainability of this interven-
tion we also assessed the duration of the effect of this
intervention and analysed the impact of the intervention
with regards to CAM and non CAM drugs.
Methods
Study design
The present study was designed as a prospective multicen-
tre observational study within the EvaMed Pharmacovigi-
lance Network, which aims to evaluate complementary
remedies in primary care with regard to prescribing pat-
terns, efficacy, and safety [19]. As the study is based on
anonymised data on adverse drug reactions which are
obligatory to report in Germany and no experimental
research or intervention on patients were applied, no eth-
ical approval was needed. Physicians were recruited
through the German National Association of Anthropo-
sophic Physicians (Gesellschaft Anthroposophischer Ärzte in
Deutschland; GAÄD). A total of 362 physicians were con-
tacted and informed about the EvaMed Network by stand-
ard mail and, in case of non-response, four weeks later by
telephone. For a physician to be eligible to participate in
the study, his or her medical practice had to meet a
number of technical requirements, including the presence
of a special computerized patient documentation system
(DocExpert, DocConcept, TurboMed, Duria, Adamed-
Plus, Medistar), a local area network (LAN) connection,
and Microsoft Windows and Internet Explorer (i.e. as cli-
ent software). A total of 38 physicians from 12 of 16 Ger-
man states fulfilled the technical requirements, gave
informed consent and agreed to participate. None of themBMC Public Health 2009, 9:274 http://www.biomedcentral.com/1471-2458/9/274
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was working in a health centre. For electronic documenta-
tion the QuaDoSta system already known by the physi-
cians was used, which has been described in detail
elsewhere [20,21]. The QuaDoSta system was free for all
physicians.
Setting
Anthroposophic medicine is a whole medical system
founded in the 1920s by Rudolf Steiner and Ita Wegman.
As a form of complementary medicine, it is regarded as an
extension to conventional treatment, requiring that a phy-
sician work together with his or her patients to under-
stand the meaning of their illness by carefully exploring
the physical, mental, and spiritual aspects of their biogra-
phy. Thus, although anthroposophic physicians employ
conventional medical treatments such as surgery and
medicine as needed, they also seek to stimulate patients'
salutogenetic capacities by using unique anthroposophic
therapies and remedies. Anthroposophic remedies
include preparations of mineral, botanical, or zoological
origin, as well as chemical substances that are either undi-
luted or based on the homeopathic principle of high dilu-
tion. Data on patients who were treated with any kind of
drug (i.e. conventional, anthroposophic, homeopathic, or
herbal) during the study period were included in the cur-
rent analysis.
Educational intervention
An interactive educational intervention was designed to
increase physician awareness of ADRs and to facilitate the
transfer of knowledge into physicians' everyday routines
(Figure 1). Starting in January 2004 the participating
physicinans documented all ADRs for 21 months in the
EvaMed network. After this time period each of the 38
physicians took part in a one-on-one ADR training ses-
sion, which lasted approximately 1.5 hours. The sessions
were held at each physician's place of work and were led
by one specially trained study researcher.
The educational intervention was divided into a theoreti-
cal and a practical part. The theoretical part consisted of a
presentation on the economic and epidemiological
importance of ADRs, as well as on the definition and clas-
sification of ADRs (i.e. in terms of seriousness, severity,
and causality). Physicians were instructed to report all
ADRs, including those that were mild or anticipated.
Every physician received a manual summarizing the main
points of the training session. The practical part of the
intervention included a problem-based learning course
that provided practical examples of how to document
ADRs using their QuaDoSta software package. Each year,
all physicians received two newsletters with details about
the study and were invited to a meeting to discuss their
experiences.
Two weeks after the educational intervention, physicians
were called and asked if they had encountered any prob-
lems; if so, they were provided with support. A telephone
hotline was available on weekdays during normal busi-
ness hours.
Data collection
The study period lasted from January 2004 through June
2007. During the study period, the participating physi-
cians continued to follow their routine documentation
procedures, recording diagnoses and prescriptions for
each consecutive patient using their existing, computer-
ized patient documentation system. These data were
exported electronically to a QuaDoSta system hosted in
each practice by an on-site server to avoid double docu-
mentation. All ADRs that occurred during the study
period were recorded by the physicians using a separate
input mask.
Because many anthroposophic physicians often prefer not
to use computers to take notes or enter data during patient
consultations, a short paper version of the computerized
Training and monitoring concept Figure 1
Training and monitoring concept.
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ADR report form was developed. This allowed physicians
to collect data by hand and transfer these to the QuaDoSta
system after the consultation. Every ADR reported to the
QuaDoSta was compensated with € 15.
The ADR report form included obligatory and voluntary
items (Table 1). ADRs were classified as serious or non-
serious according to International Conference on Harmo-
nization (ICH) guidelines [22], as well as in terms of
severity according to World Health Organization Adverse
Reaction Terminology (WHO-ART) [22].
Causality was assessed according to Uppsala Monitoring
Centre (UMC) criteria as certain, probable/likely, possi-
ble, unlikely, conditional/unclassified, or unassessable/
unclassifiable [23]. Causality assessment was based on the
nature of the ADR; the association in time between drug
administration and the ADR; possible confounding fac-
tors; the clinical plausibility of the ADR; dechallenge or
rechallenge effects; expectancy according to the informa-
tion given in the package leaflet.
An ADR report was regarded as complete if information
had been provided for all obligatory items. Physicians
were required to send their data to the study centre every
two months. In the event of a serious ADR, they had to
inform the study centre within 24 hours.
Monitoring programme
All ADR reports were monitored by the study centre and
checked for
￿ completeness (i.e. data provided for all obligatory
items)
￿ plausibility (e.g. association in time between drug
administration and ADR)
￿ classification of ADR seriousness and severity according
to ICH and WHO-ART criteria
￿ assessment of causality according to UMC criteria
To assess the quality of reports, the study centre per-
formed its own assessment of reported ADRs according to
ICH, WHO-ART, and UMC criteria. These steps took place
independently of the participating physicians. Subse-
quently, the study centre phoned the physicians to con-
firm that their reports had been received and asked them
to supply any missing data. The study centre also provided
the physicians with information about ADRs that had
been reported in the past or described in the literature in
association with the drug in question. The whole data col-
lection period lasted for 42 months (i.e. 21 months before
and 21 months after the educational intervention).
Statistical analysis
To measure changes in the ADR reporting rate, the median
number of ADR reports and interquartile range (IQR)
were calculated before and after the educational interven-
tion. The pre-intervention and post-intervention quality
of the reports was assessed in terms of changes in the com-
pleteness of data provided for obligatory items. Interrater
reliability between the physicians and the study centre
was calculated using Cohen's kappa with a 95% confi-
dence interval (CI). For the analysis of the duration of the
effect, we followed the line of Figueiras et al. [8] and
aggregated five categories: baseline period of the first 21
month, first 4-month after intervention and respective
groups for each ensuing 4-month period respectively. The
intervention effect in each 4-month period after the edu-
cational intervention was then compared to the baseline
value. Finally we evaluated the intervention effect with
regards to the quantities of ADRs in CAM and non-CAM
medication. Changes in the classification and assessment
behaviour of physicians in terms of the severity and cau-
sality of ADRs completed our analysis.
We used Mann Whitney U-test for testing continuous data
(i.e. Number of ADRs) and chi-square test was used for
categorical data (i.e. data on ADR completeness). The
level of statistical significance was set at P < 0.05. Due to
the pre-post study design in a small group of physicians
we abstained from using additional adjusting techniques.
All analyses were performed using SPSS 15 for Windows.
Results
Physicians
From January 2004 through June 2007, a total of 38 pri-
mary care practitioners participated in the study. The aver-
age age of the physicians was 48.0 (SD ± 6.1) years and
55% were male. Of the participating physicians, 55% were
general practitioners (GPs) and 45% were specialized GPs
(23% paediatrics, 11% internal medicine, 11% other).
Adverse drug reactions
A total of 404 ADRs were reported in 381 patients during
the study period. Twenty-three patients had two ADRs.
Altogether, 20 ADRs were classified as serious and 384 as
non-serious according to ICH criteria. Of the reported
ADRs, 157 were classified according to WHO-ART as
grade 1; 203 as grade 2; 40 as grade 3; and four as grade 4.
All 20 of the serious ADRs were associated with conven-
tional drugs.
Number of ADR reports
The total number of ADR reports rose from 116 before to
288 after the educational intervention (P < 0.001), which
corresponds to an increase of 148%. A detailed overview
of reporting rates before and after the intervention is givenBMC Public Health 2009, 9:274 http://www.biomedcentral.com/1471-2458/9/274
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Table 1: Obligatory and voluntary items on the adverse drug reaction (ADR) report
Obligatory Voluntary
Patient details
Patient initials* Week of pregnancy
Date of birth* Breastfeeding? (yes/no)
Gender* Profession
Height*
Weight*
Drug
Name of drug* If used previously, was the drug tolerated at the time?
Prescribed for* Was the drug continued or read ministered after onset of ADR?
Date drug started
Date drug stopped
Suspected of causing ADR (yes/no/unsure)
Dosage
Diagnosis
Name* Type of diagnose (primary, concomitant, secondary)
ICD-10 code* Diagnosis confirmed on date
ADR
Symptom Initial worsening of symptom
Severity according to WHO-ART
Serious or non-serious according to ICH If serious, why?
Date ADR started
Date ADR stopped
Treatment of ADR completed? (yes/no) Reason for not completing treatment of ADR
Causality
* Imported electronically from the computerized patient documentation system into QuaDoStaBMC Public Health 2009, 9:274 http://www.biomedcentral.com/1471-2458/9/274
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in Figure 2. Seven physicians who reported ADRs before
the intervention did not report any ADRs after it.
Before the educational intervention, the median monthly
reporting rate was 4.00 (IQR [3.00; 7.50]). The median
number of ADRs per physician was 3.00 (IQR [0.00;
10.00]). The highest pre-intervention reporting rate (14
ADRs per month) was observed in the 21st month – i.e.
after physicians had received a newsletter reminding them
of their upcoming training session.
After the educational intervention, the median ADR
reporting rate rose to 9.00 ADRs per physician (IQR [1.50;
16.00]), and the median number of ADR reports per
month significantly increased to 14.00 (IQR [9.50;
19.50], P < 0.001). The duration of the educational inter-
vention in terms of a 4-monthly trend in total ADR report-
ing is shown in Figure 3. The quantity of the effect
decreased from a median of 21.50 (IQR [16.25; 24.50]) in
the first post-intervention period to medians of 14.00
(IQR [10.50; 16.00]), 14.50 (IQR [12.50; 20.25]) and
15.5 (IQR [11.25; 19.75]) in the next three periods. Com-
pared to baseline the postinterventional number of ADR
reportings was statistically significant higher (P < 0.005)
through the first 16 months after the intervention but not
significant in the last 4-month period (median: 8.00 (IQR
[2.75; 8.75]; P = 0.605).
A subgroup analysis of the number of ADR reports finally
revealed that the increment in ADR-reporting was solely
and highly significant (P < 0.001) related to ADRs of non
CAM drugs. While the number of ADRs of CAM remained
stable (45 pre- intervention versus 45 post- intervention),
the number of non CAM ADRs increased from 71 before
intervention to 243 after intervention.
Completeness and quality of ADR reports
Completeness
The completeness of the obligatory items on the ADR
reports, including information on all current medication,
current diagnoses with ICD 10 codes, and description of
ADR increased from 80.3% before to 90.7% after the edu-
cational intervention. The largest improvement was seen
for the item 'Drug': the completeness of the sub-item
'Dosage' increased from 66.3% before to 93.0% (P  <
0.001) after the intervention. Similarly, the completeness
of the sub-item 'Date drug stopped' increased from 62.0%
to 85.1% (P  < 0.001). Although no improvement was
seen for the sub-item 'Diagnosis name', this item was
already complete on 96.6% of the ADR reports filed
Number of adverse drug reaction (ADR) reports before and after educational intervention Figure 2
Number of adverse drug reaction (ADR) reports before and after educational intervention.BMC Public Health 2009, 9:274 http://www.biomedcentral.com/1471-2458/9/274
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before the intervention. Finally, a statistically significant
increase was observed in the completeness of the sub-item
'Serious or non-serious according to ICH' after the inter-
vention (P < 0.001). Table 2 provides a more detailed
overview of the changes in the completeness of these
important items.
Quality
To evaluate the quality of ADR reports, interrater reliabil-
ity between the physicians' and the study centre's classifi-
cation of ADRs according to ICH criteria, as well as
between the physicians' and the study centre's assessment
of causality according to UMC criteria was calculated.
There were no considerable changes in the quality of clas-
sification according to ICH criteria (pre-intervention:
kappa 0.84, 95% CI: 0.64, 1 vs. post-intervention: kappa
0.87, 95% CI: 0.73, 1). For the causality assessment
according to UMC criteria, kappa was 0.15 (95% CI: 0.08;
0.29) before and 0.43 (95% CI: 0.23; 0.63) after the edu-
cational intervention. Table 3 provides a detailed over-
view of the changes in physicians' assessment of
seriousness, severity, and causality according to ICH,
WHO-ART, and UMC criteria, respectively. Physicians
assessed causality as certain in 55.2% of the ADR reports
before the intervention, but as probable in 34.0% and
possible in 44.4% of the reports after the intervention.
Only 17.7% of the reports filed after the intervention
included a causality assessment of certain.
Duration of the educational intervention in terms of a 4-monthly trend in total ADR reporting Figure 3
Duration of the educational intervention in terms of a 4-monthly trend in total ADR reporting.BMC Public Health 2009, 9:274 http://www.biomedcentral.com/1471-2458/9/274
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In total, 57.8% of the reports before and 77.4% of the
reports after the intervention involved expected ADRs.
Discussion
This prospective, multicentre study in primary care in Ger-
many shows the effects of an educational intervention
designed to improve ADR reporting in a primary care set-
ting of CAM physicians. A significant increase both in the
quantity and quality of ADR reports was observed after
physicians took part in the intervention. This finding indi-
cates that the intervention increased physicians' aware-
ness of ADRs and that the physicians were able to transfer
the knowledge they had gained from face-to-face training
into their everyday clinical practice. The impact of the
intervention, however, was temporary.
Physicians' enhanced awareness of ADRs was reflected by
an increase in the number of ADR reports submitted
immediately after they had received the first newsletter.
During the 16 months following the educational inter-
vention, the ADR reporting rate was higher than it had
been before the intervention. Subsequently, however, the
reporting rate began to decrease and continued to do so,
on the average, throughout the remaining study period.
Table 2: Completeness of obligatory items on adverse drug reaction (ADR) reports
ADR Report Before educational intervention After educational intervention P value
n%n %
ADR 116 100 288 100
Drug
Name of drug 110 94.8 279 96.9 0.325
Prescribed for 95 81.9 262 91.0 0.010*
Date drug started 99 85.3 280 97.2 < 0.001*
Date drug stopped 72 62.0 245 85.1 < 0.001*
Suspected of causing ADR 97 83.6 274 95.1 < 0.001*
Dosage 77 66.3 268 93.0 < 0.001*
Diagnosis
Name 112 96.6 279 96.9 0.868
ICD-10 code 111 95.6 279 96.9 0.556
ADR
Symptom 106 91.4 271 94.1 0.322
Severity according to WHO-ART 109 94.0 273 94.8 0.741
Serious or non-serious according to ICH 40 34.5 170 59.0 < 0.001*
Date ADR started 100 86.2 268 93.1 0.029*
Date ADR stopped 81 69.8 233 80.9 0.016*
Treatment of ADR completed? 96 82.8 268 93.1 0.002*
Causality 94 81.0 271 94.1 < 0.001*
*Significant (chi-square-test)BMC Public Health 2009, 9:274 http://www.biomedcentral.com/1471-2458/9/274
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Similar results were found by Figueiras et al, who exam-
ined the effectiveness of educational outreach visits for
improving ADR reporting by physicians. The maximal
effect in their study was observed during the first four
months after the intervention, and the differences
remained statistically significant for 12 months [8]. In a
study of an educational initiative in drug safety, Bracchi et
al. found that training improved the rate and quality of
ADR reporting, but the effect was also of only short dura-
tion [9].
In the literature, a lack of knowledge about ADRs is often
considered to be a cause of underreporting [6,24,25]. The
results of the present study show that the degree to which
physicians were able to put the knowledge they had
gained from face-to-face training into practice was
remarkably high. This is demonstrated by an increase in
the completeness of ADR reports from 80.3% before to
90.7% after the intervention. Nevertheless, a need for
improvement was seen for the item 'Severity according to
WHO-ART', as this was complete in only 59.0% of ADR
reports after the intervention.
One focus of the educational intervention was on causal-
ity assessment. Improvements in this area were observed
following the intervention, as can be seen in the shift that
occurred from a predominance of reports indicating cer-
tain causality to reports in which causality was judged to
be probable or possible. The present study was also able
to provide some insight into ADR reporting in CAM.
Quite interestingly, the intervention did not result in an
increment in the number of reported CAM associated
ADRs but to a triplication of non CAM related ADRs.
Among patients and even CAM practitioners, there
appears to be a widespread belief that CAM is 'natural'
and therefore safe [14], which may lead to underreporting
Table 3: Changes in quantity and quality of ADR reports
Before educational intervention After educational intervention
n% n %
ADR 116 100.0 288 100.0
ICH classification (P = 0.566)
Serious 8 6.9 14 4.9
Non-serious 108 93.1 274 95.1
WHO-ART classification (P = 0.015*)
Grade 1 = mild 50 43.1 107 37.2
Grade 2 = moderate 46 39.7 157 54.5
Grade 3 = severe 18 15.5 22 7.6
Grade 4 = life threatening 2 1.7 2 0.7
Causality (P < 0.001*)
Certain 64 55.2 51 17.7
Probable/likely 24 20.7 98 34.0
Possible 19 16.4 128 44.4
Unlikely 4 3.4 5 1.7
Conditional/unclassified 0 0.0 0 0.0
Unassessable/unclassifiable 5 4.3 6 2.1
*Significant (chi-square test)BMC Public Health 2009, 9:274 http://www.biomedcentral.com/1471-2458/9/274
Page 10 of 11
(page number not for citation purposes)
of ADRs associated with herbal remedies [26]. The results
of the present study show that none of the ADRs associ-
ated with CAM were serious. A very low rate of serious
ADRs might be one explanation for the low reporting rate
observed among CAM physicians.
Spontaneous reporting systems have been developed to
detect serious, rare, and unexpected ADRs. The results of
the present study show that the proportion of expected
ADRs reported by physicians was larger after an educa-
tional intervention. Expected ADRs can be used to help
assess the safety of a drug, because they are not likely to be
reported to the spontaneous reporting systems.
Cosentino et al. recommend including pharmacovigi-
lance as a topic in continuing education programmes
[10]. Our data suggests that continuing education is an
important tool for increasing physicians' awareness of
ADRs. Based on our results and the findings of Figueras et
al. [8], we would recommend a yearly repetition of such
educational interventions.
To date, ADRs have been reported primarily by physi-
cians, but nurses and pharmacists can also play an impor-
tant role [27-29]. However, in a similar interventional
program in pharmacists the study of Herdeiro et al.
showed that educational outreach visits improved ADR
reporting in terms of quantity and relevance [30].
This study has several important limitations. Firstly,
although the reporting rate decreased towards the end of
the study, the study period was too short to evaluate long-
term effects. In future studies, it would be helpful to deter-
mine whether annual training sessions might lead to
improved results. Secondly, the study did not evaluate the
total number of prescriptions in relation to the total
number of ADR reports. Thirdly, reporting even mild and
expected ADRs requires a great deal of motivation on the
part of physicians; however, factors related to motivation
were not evaluated (e.g. by questionnaire). Finally our
study design with a concurrent control group and a small
sample size did not allow to control for external interven-
tions on the individual level (i.e. individual courses in
continuing medical education) which could possibly have
influence our results.
Conclusion
In conclusion, the results of the present study demon-
strate that an educational intervention can increase physi-
cian awareness of ADRs, and that physicians were able to
incorporate the knowledge they gained from face-to-face
training into their everyday clinical practice. The effects of
the educational intervention, however, were temporary.
Further research is needed to determine whether extended
or continuous educational measures might lead to more
durable improvements in ADR reporting rates in everyday
practice. This may be particularly important considering
the growing popularity of CAM.
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